- • Up to 20%-50%* off first purchase
- • Bulk quantities available
- • Citation Reward application
AAV ProDUCTS & SERVICE
AAV TECHNICAL RESOURCE
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
AAV-MyoAAV 2A Rep-Cap plasmid (serotype MyoAAV 2A - specific AAV RC-MyoAAV 2A plasmids) (Amp and Kanamycin) (GeneMedi Owned)
GeneMedi's MyoAAV 2A Rep-Cap plasmid supplies the AAV2 Rep (replication) proteins and the MyoAAV 2A capsid protein.
You can produce MyoAAV 2A particle in 293T cell line in high titer using GeneMedi's MyoAAV 2A Rep-Cap plasmid with GM's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.
While AAV2 naturally exhibits a broad tropism, including the ability to transduce muscle cells, MyoAAV2A would have modifications that increase its specificity and efficiency for muscle tissue. This could involve alterations to the capsid structure to improve receptor binding on muscle cells or the inclusion of muscle-specific promoters within the plasmid.
GeneMedi offers both Ampicillin (Amp) resistance and Kanamycin (Kan) resistance for the AAV Rep-Cap Plasmids.
Go to AAV
vector system
>>
Map Download
Product Description
| Cat.NO | Product Name | Organization Type | Price(In USD) | ||
|---|---|---|---|---|---|
| P-RC31 | AAV-MyoAAV 2A Rep-Cap Plasmid (Amp resistance) Size：5ug | Academic | 2062 | ||
| P-RC31 | AAV-MyoAAV 2A Rep-Cap Plasmid (Amp resistance) Size：5ug | Biotech & Pharma & Medical Device & Diagnostics | |||
| P-RC31 | AAV-MyoAAV 2A Rep-Cap Plasmid (Amp resistance) Size：5ug | CRO&CDMO& CXO&CMC& Manufacturing company |
|||
| P-RC31 | AAV-MyoAAV 2A Rep-Cap Plasmid (Amp resistance) Size：≥10mg |
All | |||
| P-RC31-Kan | AAV-MyoAAV 2A Rep-Cap Plasmid (Kan resistance) Size：≥10mg |
All | |||
| P-PK31 | AAV-MyoAAV 2A Vector
System (Amp resistance)
1. MyoAAV 2A Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug |
Academic | 3379 | ||
| P-PK31 | AAV-MyoAAV 2A Vector
System (Amp resistance)
1. MyoAAV 2A Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | Biotech & Pharma & Medical Device & Diagnostics | |||
| P-PK31 | AAV-MyoAAV 2A Vector
System (Amp resistance)
1. MyoAAV 2A Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | CRO&CDMO& CXO&CMC& Manufacturing company |
|||
| P-PK31 | AAV-MyoAAV 2A Vector
System (Amp resistance)
1. MyoAAV 2A Rep-Cap Plasmid, ≥10mg 2. AAV Helper Plasmid, ≥10mg 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01-Kan), ≥10mg |
All | |||
| P-PK31-Kan | AAV-MyoAAV 2A Vector
System(Kan resistance)
1. MyoAAV 2A Rep-Cap Plasmid(Kan resistance), ≥10mg 2. AAV Helper Plasmid(Kan resistance), ≥10mg 3. pGMAAV-CMV-MCS-T2A-ZsGreen (Kan resistance) (P-AAVV-B01-Kan), ≥10mg |
All | |||
|
GeneMedi offers both seed and amplification services for the Amp-resistant AAV Rep-Cap Plasmid. GeneMedi only offers amplification services and do not provide seed for the Kan-resistant AAV Rep-Cap Plasmid currently. |
|||||
| If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service. | |||||
|
Terms of sale: For Seed (5ug): The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for any other party. For plasmid production& amplification (≥10mg): The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for themselves or any other party. |
|||||
Citation
| Title | Publication | Date |
|---|---|---|
| Exerkine fibronectin type-III domain-containing protein 5/irisin-enriched extracellular vesicles delay vascular ageing by increasing SIRT6 stability | European Heart Journal | 2022/8/5 |
| Targeting Nestin+ hepatic stellate cells ameliorates liver fibrosis by facilitating TβRI degradation | JOURNAL OF HEPATOLOGY | 2021/5/1 |
| Exosomes derived from impaired liver aggravate alveolar bone loss via shuttle of Fasn in type 2 diabetes mellitus | Bioactive Materials | 2023/11/9 |
| circCIMT Silencing Promotes Cadmium‐Induced Malignant Transformation of Lung Epithelial Cells Through the DNA Base Excision Repair Pathway | Advanced Science | 2023/2/22 |
| RING finger protein 13 protects against nonalcoholic steatohepatitis by targeting STING-relayed signaling pathways | Nature Communications | 2023/10/20 |
| ADAMTS7-Mediated Complement Factor H Degradation Potentiates Complement Activation to Contributing to Renal Injuries | Journal of the American Society of Nephrology | 2023/2/1 |
| The mitochondrial β-oxidation enzyme HADHA restrains hepatic glucagon response by promoting β-hydroxybutyrate production | Nature Communications | 2022/1/19 |
| The Agpat4/LPA axis in colorectal cancer cells regulates antitumor responses via p38/p65 signaling in macrophages | Signal Transduction and Targeted Therapy | 2020/3/27 |
| Fusobacterium nucleatum outer membrane vesicles activate autophagy to promote oral cancer metastasis | Journal of Advanced Research | 2023/4/13 |
| Site-specific ubiquitination of VDAC1 restricts its oligomerization and mitochondrial DNA release in liver fibrosis | Experimental & Molecular Medicine | 2023/1/19 |
Validation data
No data found
Associated products and services
| Products & Service | Products & Service Information |
|---|---|
| AAV Packaging service | Detail |
| Promise-ORF™ viral CDNA library | Detail |
| Plasmid DNA Rapid Preparation Service | Detail |
Facebook
LinkedIn
Twitter
